Maduck Sean sold $419K of CORT

Maduck Sean (See Remarks) sold 3,664 shares of CORCEPT THERAPEUTICS INC (CORT) at $114.49 ($0.42M total) on 2026-08-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Maduck Sean
Published Aug 18, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 9:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
high confidence
Mentioned
$CORT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

The only new fact is the size, price, and timing of the officer’s open-market sale under a 10b5-1 plan; it does not include guidance, trial results, regulatory actions, or deal terms.

02

Market read

Traders may note insider selling, but the 10b5-1 structure and lack of accompanying fundamentals make this more of a sentiment datapoint than a catalyst.

03

What to watch

The filing does not indicate whether the sale was tax-related, diversification-related, or part of a scheduled liquidity program; without additional context, signal quality is low.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-18 after-hours; reflects sale executed 2026-08-14

Background

The article is a SEC Form 4 insider transaction report for Corcept Therapeutics, filed on 2026-08-18, covering a sale executed 2026-08-14.

Company-level read

Ticker impact

$CORTNeutralHigh confidence
Context

Corcept Therapeutics disclosed an officer open-market sale of 3,664 shares at $114.49 on 2026-08-14 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived unless accompanied by other news.

Evidence & confidence

Form 4 details a pre-arranged 10b5-1 sale and provides no new company-specific information beyond the transaction itself.

Market effects

Minimal; insider-sale Form 4s typically do not reset sector expectations for pharma/biotech.

None indicated.

None indicated.

Counterpoint

10b5-1 plans can lead to regular selling regardless of outlook, so the disclosure may be misread as bearish.

Key entities

  • Corcept Therapeutics Inc

    Subject of the Form 4 insider transaction disclosure (ticker CORT).

  • Maduck Sean

    Officer who sold 3,664 shares at $114.49 under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.